Navigation Links
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST

TORONTO, Feb. 9 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, February 11, 2009 at 4:30 P.M. EST to discuss the Second Quarter fiscal 2009 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call 1(800) 771-6781 (North America), 1(212) 231-2901 (International). A replay of the conference call will be available on Transition's website for seven days following the call.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CDS Completes Large-Scale Transition of Medicare Data Processing
2. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
3. Is rapid transition through menopause linked to earlier onset of heart disease?
4. MEDai Presents on Transitioning Predictive Modeling Integration From Care Management to Actuarial Applications
5. Mental Health Leaders Meet with Transition Team
6. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
7. AUDIO from Medialink and Transitions Optical: New Years Resolutions for Healthier Eyes
8. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
9. SantaFe Senior Living Announces Leadership Transition
10. ConnextionsHealth Introduces Member Transition Services to Assist Health Plans in Efforts to Retain Members During Life Cycle Changes
11. Courage Center Transitional Rehabilitation Program to Participate in Learning Collaborative With Stratis Health
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... of non-traumatic limb amputations in the United States. Podiatrists are well aware that ... to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Center of Excellence (BHCOE) today announced that the organization has awarded Education and ... Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers that ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
(Date:12/1/2015)... Beverly Hills, CA (PRWEB) , ... December 01, ... ... honored by Modern Luxury’s Angeleno Magazine as a Modern Man for 2015. ... luxury lifestyle publisher in the United States. Established in 1994, Modern Luxury includes ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
Breaking Medicine Technology: